The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| OCS | +38.4% | N/A | N/A | +198% |
| S&P | +14.39% | +76.41% | +12.02% | +68% |
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.
No news articles found for Oculis Ag.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$188.68K | -37.4% |
| Market Cap | $958.70M | 87.3% |
| Market Cap / Employee | $19.57M | 0.0% |
| Employees | 49 | 0.0% |
| Net Income | -$21,061.31K | 9.6% |
| EBITDA | -$25,476.00K | -21.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $58.37M | 38.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.57M | 133.4% |
| Short Term Debt | $529.13K | 42.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -67.47% | -13.1% |
| Return On Invested Capital | -89.06% | -9.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$17,972.46K | -39.9% |
| Operating Free Cash Flow | -$17,812.80K | -40.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 6.32 | 10.26 | 5.50 | 5.33 | 30.97% |
| Price to Tangible Book Value | 7.25 | 12.53 | 5.99 | 5.88 | 28.77% |
| Enterprise Value to EBITDA | -31.71 | -31.88 | -32.18 | -29.09 | 57.33% |
| Return on Equity | -101.3% | -85.4% | -81.0% | -87.6% | 26.91% |
| Total Debt | $1.30M | $1.25M | $1.29M | $3.10M | 110.33% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
